Showing results (51-60 of 72) with videos related to
Sort By:
Pageof 8
Clinical Pharmacokinetics|March 10, 2018
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic ImpairmentErik Mogalian, Diana M Brainard, Anu Osinusi, et al.Journal of Clinical Pharmacology|February 20, 2004
Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairmentJun Shi, Guy Montay, Sunny Chapel, et al.Investigational New Drugs|July 3, 2010
Influence of mild and moderate hepatic impairment on axitinib pharmacokineticsMichael A Tortorici, Melvin Toh, S V Rahavendran, et al.Journal of Clinical Pharmacology|April 11, 2015
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairmentKimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, et al.Journal of Clinical Pharmacology|December 31, 2013
Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairmentThomas Marbury, Eric Lawitz, Robert Stonerock, et al.Drug Development Research|March 21, 2014
The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabineJoshua Haznedar, Sebastian Moreira, Thomas Marbury, et al.Journal of Hepatology|February 9, 2012
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis CEric J Lawitz, Daniel Gruener, John M Hill, et al.Antiviral Therapy|October 11, 2012
A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patientsEric J Lawitz, John M Hill, Thomas Marbury, et al.Journal of Clinical Pharmacology|December 13, 2021
Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic ImpairmentYan Xu, Raquel Izumi, Helen Nguyen, et al.Clinical Pharmacokinetics|May 25, 2005
Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitantArthur J Bergman, Thomas Marbury, Trisha Fosbinder, et al.Pageof 8